Shire (SHPG) Ticks Higher Following Adverse Events in Roche's ACE910 Trial

November 3, 2016 9:18 AM EDT

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Gains in Shire plc (NASDAQ: SHPG) Thursday morning were tied to adverse events in Roche's ACE910 trial. The trial recorded two thromboembolic and two thrombotic microangiopathy events, according to Bloomberg, citing an email. The study is continuing.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Trader Talk

Add Your Comment